| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | TOP2; TP2A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human TOP2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TOP2A抗体的3篇参考文献，包含文献名称、作者及摘要概括：
1. **文献名称**：*"TOP2A amplification in breast cancer: a dual-color FISH study on tissue microarrays"*
**作者**：Järvinen TA, Tanner M, Rantanen V, et al.
**摘要**：研究利用TOP2A抗体和荧光原位杂交(FISH)技术分析乳腺癌组织中TOP2A基因的扩增情况，发现其与蒽环类化疗药物敏感性相关，提示TOP2A可作为治疗反应预测标志物。
2. **文献名称**：*"Co-amplification and prognostic value of HER2 and TOP2A in invasive breast cancer"*
**作者**：O'Malley FP, Chia S, Tu D, et al.
**摘要**：通过免疫组化(IHC)和FISH检测乳腺癌样本中HER2与TOP2A的共扩增，发现TOP2A扩增与患者较差的无病生存期相关，并可能影响靶向治疗策略。
3. **文献名称**：*"Topoisomerase IIα as a marker of cell proliferation and prognosis in colorectal cancer"*
**作者**：Alonso-Alconada L, Muinelo-Romay L, Madissoo K, et al.
**摘要**：研究评估TOP2A抗体在结直肠癌组织中的表达水平，证实其高表达与细胞增殖活性升高及患者预后不良相关，提示其在肿瘤进展中的关键作用。
以上文献均聚焦于TOP2A抗体在癌症诊断、治疗预测及预后评估中的应用。
TOP2A (DNA topoisomerase II alpha) is a nuclear enzyme critical for DNA replication, transcription, and chromosome segregation by regulating DNA topology during cell division. The TOP2A gene encodes this enzyme, which is highly expressed in proliferating cells, particularly during the G2/M phase of the cell cycle. Dysregulation of TOP2A is implicated in cancer development, as its overexpression or genetic alterations (e.g., amplifications, deletions) are linked to tumor aggressiveness, genomic instability, and therapeutic resistance.
Antibodies targeting TOP2A are widely used in research and diagnostics to assess protein expression levels in tissues, often via immunohistochemistry (IHC). In clinical settings, TOP2A status is evaluated alongside HER2 in breast cancer to guide treatment decisions, as TOP2A co-amplification with HER2 may predict sensitivity to anthracycline-based chemotherapy. Additionally, TOP2A antibodies help study drug mechanisms, such as the action of topoisomerase inhibitors (e.g., etoposide, doxorubicin), which trap TOP2A-DNA complexes to induce lethal DNA breaks. However, TOP2A testing remains controversial due to variability in antibody performance, assay standardization challenges, and conflicting evidence regarding its standalone prognostic value. Despite this, it remains a biomarker of interest in oncology for understanding cell proliferation dynamics and optimizing targeted therapies.
×
